title: Serum lipid profiles in patients receiving endocrine treatment for breast cancer--the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial.
abstract: BACKGROUND
  Anti-aromatase therapy is important in the treatment of breast cancer. Cyclooxygenase-2 (COX-2) inhibitors may be effective in chemoprevention. A proof of principle study was performed to investigate the efficacy and side effects including changes in lipid profiles of combining anti-aromatase therapy and COX-2 inhibitor preoperatively in hormone sensitive postmenopausal breast cancers.
  
  
  METHODS
  From February 2002 to April 2003, 41 postmenopausal women with histologically proven LABC were recruited. The patients were randomly assigned to receive exemestane 25 mg daily and celecoxib 400 mg twice-daily (group A), exemestane 25 mg daily (group B) and letrozole 2.5 mg daily (group C.
  
  
  RESULTS
  Observed clinical response rates were 61.5%, 60% and 54.5% for Groups A-C, respectively, with no pathologic complete response. Cholesterol levels for Group A dropped progressively and a statistical difference was observed between fifth week after operation and preoperative level (P = 0.026). In addition, Group A has significantly lowered cholesterol and LDL levels than Groups B and C after 18 weeks of treatment.
  
  
  CONCLUSIONS
  The initial results show that different neoadjuvant anti-aromatase therapies has similar efficacy but the combination with celecoxib may have an advantageous effects on the serum lipid profiles.
authors.affiliation: Department of Surgery, Hung Chao Hong Integrated Center for Breast Diseases, University of Hong Kong Medical Center, Queen Mary Hospital, Pokfulam. lwcchow@hkucc.hku.hk
authors.forename: L W C
authors.initials: LW
authors.lastname: Chow
authors.forename: C W L
authors.initials: CW
authors.lastname: Cheng
authors.forename: J L N
authors.initials: JL
authors.lastname: Wong
authors.forename: M
authors.initials: M
authors.lastname: Toi
mesh_terms: D000368:Aged; D000730:Androstadienes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy*; D000068579:Celecoxib; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D011720:Pyrazoles / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D000730:Androstadienes; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D052246:Cyclooxygenase 2 Inhibitors; D004791:Enzyme Inhibitors; D008055:Lipids; D011720:Pyrazoles; D013449:Sulfonamides; D014280:Triglycerides; D002784:Cholesterol; D000068579:Celecoxib; C056516:exemestane